• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BRAF 和 NRAS 基因突变在皮肤黑色素瘤的组织学类型和起源部位中的频率不同:一项荟萃分析。

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.

机构信息

Department of Pathology, Korea University Ansan Hospital, 516, Gojan-1 Dong, Danwon-Gu, Ansan-Si, Gyeonggi-Do 425-707, Korea.

出版信息

Br J Dermatol. 2011 Apr;164(4):776-84. doi: 10.1111/j.1365-2133.2010.10185.x. Epub 2011 Mar 21.

DOI:10.1111/j.1365-2133.2010.10185.x
PMID:21166657
Abstract

BACKGROUND

There have been conflicting data regarding the prevalence and clinicopathological characteristics of BRAF and NRAS mutations in primary cutaneous melanoma.

OBJECTIVES

To solve this controversy, this study used a meta-analysis to evaluate the frequencies of BRAF and NRAS mutations, and the relationship between these mutations and clinicopathological parameters of cutaneous melanoma.

METHODS

Data from studies published between 1989 and 2010 were combined. The BRAF and NRAS mutations were reported in 36 and 31 studies involving 2521 and 1972 patients, respectively. The effect sizes of outcome parameters were calculated by odds ratios (OR).

RESULTS

BRAF and NRAS mutations were reported in 41% and 18% of cutaneous melanomas, respectively. The mutations were associated with histological subtype and tumour site, but not with age and sex. The BRAF mutation was frequently detected in patients with superficial spreading melanoma (OR=2·021; P<0·001) and in melanomas arising in nonchronic sun-damaged skin (OR=2·043; P=0·001). In contrast, the NRAS mutation was frequently evident in patients with nodular melanoma (OR=1·894; P<0·001) and in melanomas arising in chronic sun-damaged skin (OR=1·887; P=0·018).

CONCLUSIONS

This pooled analysis shows that the incidences of BRAF and NRAS mutations in cutaneous melanomas differ according to histological type and tumour location based on the degree of sun exposure.

摘要

背景

关于原发性皮肤黑素瘤中 BRAF 和 NRAS 突变的流行率和临床病理特征,存在相互矛盾的数据。

目的

为了解决这一争议,本研究采用荟萃分析来评估 BRAF 和 NRAS 突变的频率,以及这些突变与皮肤黑素瘤临床病理参数之间的关系。

方法

合并了 1989 年至 2010 年间发表的研究数据。有 36 项研究报告了 BRAF 突变,涉及 2521 例患者;有 31 项研究报告了 NRAS 突变,涉及 1972 例患者。通过比值比(OR)计算结局参数的效应大小。

结果

BRAF 和 NRAS 突变分别在 41%和 18%的皮肤黑素瘤中被报道。这些突变与组织学亚型和肿瘤部位相关,但与年龄和性别无关。BRAF 突变在浅表扩散性黑素瘤(OR=2.021;P<0.001)和非慢性日光损伤皮肤的黑素瘤(OR=2.043;P=0.001)患者中频繁检出。相比之下,NRAS 突变在结节性黑素瘤(OR=1.894;P<0.001)和慢性日光损伤皮肤的黑素瘤(OR=1.887;P=0.018)患者中频繁出现。

结论

这项汇总分析表明,BRAF 和 NRAS 突变在皮肤黑素瘤中的发生率根据组织学类型和肿瘤位置而有所不同,这与日照程度有关。

相似文献

1
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.BRAF 和 NRAS 基因突变在皮肤黑色素瘤的组织学类型和起源部位中的频率不同:一项荟萃分析。
Br J Dermatol. 2011 Apr;164(4):776-84. doi: 10.1111/j.1365-2133.2010.10185.x. Epub 2011 Mar 21.
2
Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.皮肤黑色素瘤亚型显示出不同的BRAF和NRAS突变频率。
Clin Cancer Res. 2006 Aug 1;12(15):4499-505. doi: 10.1158/1078-0432.CCR-05-2447.
3
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.黑色素瘤肿瘤中NRAS和BRAF突变与临床特征的关系:一项基于焦磷酸测序进行突变筛查的研究
Melanoma Res. 2006 Dec;16(6):471-8. doi: 10.1097/01.cmr.0000232300.22032.86.
4
Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.通过 array 比较基因组杂交揭示 BRAF 和 NRAS 突变原发性黑色素瘤之间明显的遗传差异。
Melanoma Res. 2012 Jun;22(3):202-14. doi: 10.1097/CMR.0b013e328352dbc8.
5
Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.原发性皮肤黑色素瘤的临床病理特征及突变分析
Am J Dermatopathol. 2015 May;37(5):389-97. doi: 10.1097/DAD.0000000000000241.
6
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.黑色素瘤患者原发肿瘤和转移灶中 BRAF/NRAS 突变频率。
J Clin Oncol. 2012 Jul 10;30(20):2522-9. doi: 10.1200/JCO.2011.41.2452. Epub 2012 May 21.
7
Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.皮肤镜特征与原发性皮肤黑色素瘤中 BRAF 和 NRAS 突变状态相关。
Br J Dermatol. 2014 Oct;171(4):754-9. doi: 10.1111/bjd.13069. Epub 2014 Sep 10.
8
Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.NRAS 基因突变与皮肤黑色素瘤临床结局及病理特征的相关性。
Pigment Cell Melanoma Res. 2011 Aug;24(4):666-72. doi: 10.1111/j.1755-148X.2011.00873.x. Epub 2011 Jun 22.
9
Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.评估与转移性恶性黑色素瘤突变状态相关的临床参数:对 141 例患者的单中心研究。
Br J Dermatol. 2013 Apr;168(4):708-16. doi: 10.1111/bjd.12140.
10
BRAF and NRAS mutations in melanoma and melanocytic nevi.黑色素瘤和黑素细胞痣中的BRAF和NRAS突变
Melanoma Res. 2006 Aug;16(4):267-73. doi: 10.1097/01.cmr.0000222600.73179.f3.

引用本文的文献

1
Clinical, Histopathological, Dermoscopic Features, and , , and Cell Cycle Genes' Mutation Status in Cutaneous Melanoma.皮肤黑色素瘤的临床、组织病理学、皮肤镜特征以及细胞周期基因的突变状态
Cancers (Basel). 2025 Aug 19;17(16):2688. doi: 10.3390/cancers17162688.
2
A systematic review of microsimulation models for skin cancer.皮肤癌微观模拟模型的系统评价。
BMC Med Inform Decis Mak. 2025 Jul 1;25(1):222. doi: 10.1186/s12911-025-03074-9.
3
Biliary Adenofibroma and the Threat of Malignant Transformation.胆管腺纤维瘤与恶性转化风险
Int J Surg Pathol. 2025 Oct;33(7):1658-1665. doi: 10.1177/10668969251331176. Epub 2025 Apr 13.
4
Exploiting Paradoxical Activation of Oncogenic MAPK Signaling by Targeting Mitochondria to Sensitize Mutant-Melanoma to Vemurafenib.通过靶向线粒体利用致癌性丝裂原活化蛋白激酶(MAPK)信号的矛盾激活使突变型黑色素瘤对维莫非尼敏感
Int J Mol Sci. 2025 Mar 16;26(6):2675. doi: 10.3390/ijms26062675.
5
Paradigm of biomarkers in metastatic melanoma (Review).转移性黑色素瘤中生物标志物的范例(综述)
Oncol Lett. 2024 Nov 26;29(2):78. doi: 10.3892/ol.2024.14824. eCollection 2025 Feb.
6
Evidence for Radiation Therapy in Stage III Locoregionally Advanced Cutaneous Melanoma in the Post-Immunotherapy Era: A Literature Review.免疫治疗时代后 III 期局部晚期皮肤黑色素瘤放射治疗的证据:文献综述
Cancers (Basel). 2024 Aug 30;16(17):3027. doi: 10.3390/cancers16173027.
7
Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.手术在转移性黑色素瘤中的作用及黑色素瘤分子特征综述。
Cells. 2024 Mar 7;13(6):465. doi: 10.3390/cells13060465.
8
Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120's Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines.跨物种比较泛 RAF 抑制剂 LY3009120 在马、犬和人恶性黑素瘤细胞系中的抗肿瘤作用。
Genes (Basel). 2024 Feb 3;15(2):202. doi: 10.3390/genes15020202.
9
A literature review of a meta-analysis of BRAF mutations in non-small cell lung cancer.非小细胞肺癌 BRAF 突变的荟萃分析文献综述。
Medicine (Baltimore). 2024 Feb 23;103(8):e34654. doi: 10.1097/MD.0000000000034654.
10
Melanoma biology and treatment: a review of novel regulated cell death-based approaches.黑色素瘤生物学与治疗:基于新型程序性细胞死亡方法的综述
Cancer Cell Int. 2024 Feb 9;24(1):63. doi: 10.1186/s12935-024-03220-9.